NCT06711523View on ClinicalTrials.gov

Study Evaluating PEG-G-CSF Injectionin Preventing Neutropenia After Chemotherapy

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

December 31, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Neutropenia, Chemotherapy-Induced FebrileBreast Neoplasm Female
Interventions
DRUG

PEG-G-CSF injection (Kexing Biopharmaceutical Co., Ltd.)

This trial was conducted using the IWRS system where subjects were randomly assigned to the test group (PEG-G-CSF injection (Kexing Biopharmaceutical Co., Ltd.)) and control group (Neulasta®，Amgen Europe B.V.) in a 1:1 ratio.

DRUG

PEG-G-CSF injection (Neulasta®，Amgen Europe B.V.)

This trial was conducted using the IWRS system where subjects were randomly assigned to the test group (PEG-G-CSF injection (Kexing Biopharmaceutical Co., Ltd.)) and control group (Neulasta®，Amgen Europe B.V.) in a 1:1 ratio.

Trial Locations (1)

100142

Beijing Cancer Hospital, Beijing

Sponsors
All Listed Sponsors
lead

Kexing Biopharm Co., Ltd.

INDUSTRY

NCT06711523 - Study Evaluating PEG-G-CSF Injectionin Preventing Neutropenia After Chemotherapy | Biotech Hunter | Biotech Hunter